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                                                         ABSTRACT 
Objective 
To determine if there is an increased risk of delirium among patients with 
overactive bladder (OAB) started on anticholinergic medication compared to beta-3 
agonist. 
Methods 
We conducted a population-based, retrospective, matched weight cohort study 
using administrative data from Ontario, Canada from January 2016 until March 2020.  
We matched 13865 new users of Oxybutynin to 33097 new users of newer 
anticholinergic medications (Solifenacin, Tolterodine, Trospium, Darifenacin and 
Fesoterodine), and to 56062 new users of beta-3 agonist medication (Mirabegron); all 
of the included medications are only used for the treatment of OAB. Matching weights 
(an extension of the propensity score weighting) were used to balance the three exposure 
groups based on 83 measured indicators of baseline health, comorbidity, medication 
usage and health care utilization. The primary exposure was the class of OAB 
medication (Oxybutynin, Newer anticholinergics, and Beta-3 agonist). The primary 
outcome was delirium using a validated administrative data definition. Logistic 
regression, and proportional hazards analysis were used to assess outcomes at 30 days, 
and during continuous use of the medications. 
Results 
The median (IQR) duration of continuous usage was 113 (30-380) days for Beta-
3 agonist, 30 (28-72) days for Oxybutynin, and 62 (30-239) days for the newer 
anticholinergics. There was no increased risk of delirium in primary analysis among 
Oxybutynin and newer anticholinergics drug users compared to beta-3 agonist at the 30 
days observational window (odds ratio 1.28, 95% CI 0.84-1.96, p=0.25 for Oxybutynin 
and OR 0.92, 95% CI 0.58-1.46, p=0.73 for newer anticholinergics). The secondary 
analysis accounting for the period of continuous use showed a small but significant  
increased risk of delirium with the use of newer anticholinergics drugs compared to 
beta-3 agonist (HR 1.13, 95% CI 1.02-1.26 for newer anticholinergics). 
Conclusions 
The use of anticholinergic medications among patients with OAB was not 
associated with a significantly increased risk of delirium compared to beta-3 agonist 
users at 30 days; however, the risk is slightly increased with continuous usage of newer 
anticholinergic medications. 
Keywords 




Summary for Lay Audience 
Overactive bladder (urgency with or without incontinence, frequency and 
nocturia) is a common condition in 10-15% of the population with many bladder 
medications being used to control this condition.  These medications act on the action 
of a brain chemical known as Acetylcholine. Recent studies suggest long term use of 
these medications may cause cognitive decline and dementia. Annually, 25,000 
Canadians are diagnosed with dementia with an annual cost of over $12 billion spent to 
care for those living with dementia. 
The currently approved anticholinergic medications used in Canada can be 
divided into two main categories: (1) Oxybutynin (the first medication approved for 
OAB in the 1970’s); and (2) more recent medications (Tolterodine, Solifenacin, 
Darifenacin, Fesoterodine and Trospium). 
The ODPRN (Ontario Drug Policy Research Network) final consolidation report from 
March 2016 recommended Oxybuytnin as the initial treatment for patients with overactive 
bladder syndrome while reserving the newer medications for intolerance or failure of 
Oxybutynin, and requiring a limited use code for coverage by the Ontario Drug Plan.  
Therefore Oxybutynin continues to be the sole first-line treatment option available on this 
plan. 
This policy may be depriving people from medication that might be better 
tolerated, equally or more effective, and possibly safer than Oxybutynin, a very old 
overactive bladder agent, which has clearly been associated with dementia and 
cognitive impairment versus newer drugs like Fesoterodine or Mirabegron. 
Older overactive bladder medications are linked to new onset of dementia and 
there are case reports reporting delirium associated with anticholinergic medications. 
We conducted this study to assess the actual risk of delirium and to see if these results 
might change the policy of general OAB drug use implemented by Ontario Drug 
Benefit. We did not demonstrate a risk of delirium associated with anticholinergics 
compared to the only beta-3 agonist (Mirabegron,) in the 30 days period, however 
during longer use we found  an increased risk of delirium is associated with newer 
anticholinergic medications compared to mirabegron. 
Our results confirm that anticholinergics should be used with caution in elderly 
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Understanding Overactive Bladder  
Lower urinary tract symptom (LUTS) terminology was first introduced in 1994 
[1]. The International Continence Society (ICS) defines LUTS as symptoms attributed 
to urinary storage (increased daytime frequency, nocturia of at least one episode/night, 
urgency and urgency incontinence), voiding (slow or intermittent stream during 
micturition, splitting or spraying of the urine stream, straining, hesitation, terminal 
dribble) and postmicturition (feeling of incomplete emptying and postmicturition 
dribble) [2]. LUTS are a common health problem experienced by adults with prevalence 
increasing with age [3]. Overactive bladder (OAB) is a storage subset of LUTS defined 
by ICS as urgency with or without urgency urinary incontinence (UUI), commonly 
associated with frequency and nocturia [2]. The ICS also acknowledged within the 
definition that these symptoms are usually suggestive of urodynamically demonstrable 
detrusor overactivity but can be due to other forms of urethravesical dysfunction [2]. 
The Lower Urinary tract 
Neurotransmission 
Detrusor muscle contraction is achieved by acetylcholine activation of the 
muscarinic receptors [4-6]. The muscarinic receptor subtypes identified in the human 
bladder are M1-M3 [5]. M1 controls the release of acetylcholine in the bladder [7]. The 
predominate muscarinic receptor in the human bladder appears to be M2, however it 
appears that the cholinergic-induced contractions of the detrusor are mediated through 
M3 receptors [6]. 
Overactive bladder 
OAB, as previously defined, is urinary urgency, with or without urge 
incontinence, and is commonly associated with frequency and nocturia [2].  Urgency, 
the cornerstone in the diagnosis of OAB, is the compelling desire to void that is difficult 
to defer [2]. OAB-dry is a term used for patients who experience symptoms of OAB 
without urge incontinence [8]. Frequency is defined as voiding too frequently during 
the day and nocturia is the complaint of waking during the night to void. Both frequency 




OAB symptoms may be from involuntary detrusor muscle contractions [4]. 
Detrusor overactivity, whether neurogenic (Neurologic cause), myogenic (Muscular 
cause), or idiopathic (no defined cause) are characterized by involuntary contractions 
of the detrusor muscle during the filling phase which can be either spontaneous or 
provoked [2,4]. The involuntary detrusor contraction can take place at any bladder 
volume, but usually happens at a bladder capacity < 200 mL [4].  
Age-related causes of urinary dysfunction 
OAB is a common health problem affecting 10-15 % of the population [1]. In  
elderly, it is attributed to increased risk of falls which, in turn, can lead to hip fractures, 
anxiety/depression, and social withdrawal with a remarkable impact on the quality of 
life [9,10]. The economic burden of OAB is significant, reaching over $14 billion [11]. 
The elderly population has special considerations when dealing with OAB such as 
polypharmacy, multimorbidity, functional and cognitive impairment, frailty as well as 
postmenopausal estrogen status in women [12]. 
Polypharmacy can have an adverse impact on normal bladder function and worsen 
OAB symptoms, or adversely interact with OAB medications affecting their 
bioavailability and metabolism [13-15]. Multimorbidity is defined as the presence of 
two or more chronic medical conditions. Elderly patients with OAB are likely to have 
3-5 concomitant diseases with diabetes, hypertension and hyperlipidemia being the 
most prevalent [16]. This puts them at high risk of polypharmacy and drug-drug 
interactions. 
Poorly controlled diabetes plays a major role; the prolonged exposure to 
hyperglycemia results in damage to detrusor muscle and bladder innervation through 
oxidative stress, leading to diabetic cystopathy. Diabetic cystopathy is a triad of 
decreased bladder sensation, increased bladder capacity and poor bladder emptying 
which can exacerbate an underlying OAB symptom [17,18].  
Hypertension and congestive heart failure are other conditions affecting OAB in 
which some treatment medications such as diuretics can counteract the effect of OAB 
medications. The functional limitations associated with neurologic diseases such as 
Parkinson’s disease (PD), Multiple sclerosis and cerebrovascular accidents, can 




Cholinesterase inhibitors (ChIs) are the mainstay of treatment for PD, therefore, the 
concomitant use of ChI with an antimuscarinic medication (majority of the OAB 
medications) can diminish ChI therapy and potentially exacerbate cognitive decline 
[19]. Hypoestrogenism contributes to worsening OAB symptoms through urogenital 
atrophy with subsequent urgency, frequency, nocturia, incontinence and recurrent  
urinary tract infections [20]. Low dose vaginal estrogen has been associated with 
increased bladder sensation with improved frequency, urgency, and bladder capacity 
[21]. 
Treatment of overactive bladder 
First line treatment: Behavioral Therapies 
Behavioral therapies, including bladder training (timed voiding and urge 
suppression techniques), fluid management and pelvic floor muscle training (PFMT) 
with increased physical activity, help to overcome functional limitations [22,23]. PFMT 
aims at voluntary contractions of pelvic floor muscles to suppress the detrusor 
overactivity, augment urethral support and overcome urine loss associated with 
urgency. PFMT alone has shown a reduction of incontinence ranging from 60-80% in 
controlled trials aiming to suppress urge through PFMT [24]. However, these methods 
require continued motivation and effort by the patient. 
Second line treatment: Oral Anti-Muscarinic or Beta 3 Adrenoreceptor Agonist 
The oral anti-muscarinic (anti-cholinergic) medications have been the main 
therapy for OAB. The use of these medications represent a challenge for elderly patients 
complaining of OAB symptoms arising from the polypharmacy which often exists in 
this vulnerable group, in conjunction with increased medication side effects together 
with medication noncompliance. Medications used for the treatment of other 
concomitant comorbidities such as digoxin, warfarin, ranitidine, and diazepam have 
anti-muscarinic properties which will increase the anti-muscarinic drug load and 
consequently, the anti-muscarinic side effects when used conjointly with OAB 
medications. A higher anti-muscarinic load can predispose older patients to cognitive 





Oxybutynin (one of the oldest OAB medications) is associated with the highest 
risk of cognitive impairment. Oxybutynin is available in several preparations and doses 
with the transdermal preparation being most preferred to be used in older patients in 
order to avoid the first pass metabolism [27]. Extended-release forms of both 
Oxybutynin and Tolterodine are recommended due to less side effects especially dry 
mouth. Fesoterodine demonstrated good efficacy with similar side effect profiles in 
older populations when compared to younger population [28,29].  P-glycoprotein (P-
gp) is the best studied transporter limiting blood brain barrier (BBB) penetration, Brain 
penetration is low for antimuscarinics that are P-gp substrates (Darifenacin and 
Trospium), and significant for those that are not P-gp substrates (Oxybutynin, 
Solifenacin and Tolterodine) [30]. The unique structure and hydrophilic properties of 
Trospium, a quaternary amine, make it the least likely to cross the BBB and therefore 
less likely to cause cognitive impairment. A randomized double-blind placebo-
controlled trial aimed at investigating the effect of Trospium chloride on cognitive 
function in postmenopausal women treated for OAB showed no change in cognitive 
function between Trospium and placebo [31]. 
Mirabegron, the only approved Beta 3 adrenoreceptor agonist, stimulates the Beta 
3 receptor in the bladder resulting in detrusor muscle relaxation. The bladder expresses 
97% of all Beta 3 receptors; however, Beta 3 receptors are also expressed in the 
cardiovascular system where it mediates vasodilation by increasing atrial contractions 
[32,33]. The safety of Mirabegron at various doses show a minimal increase in blood 
pressure (BP) and heart rate (HR) [32]. Blood pressure and heart rate monitoring are 
recommended following the start of Mirabegron. 
Anticholinergic drugs seem to have the same efficacy in managing OAB 
symptoms [33,34], however, because of different selectivity for muscarinic receptor 
subtype, they vary in their safety and tolerability profile [35-39]. The current data 
showed that Darifenacin has the highest M3 selectivity (which is the muscarinic 
receptor most abundant in bladder and responsible for the effect of anticholinergic 
medications on OAB symptoms) over other receptor subtypes (M1, M2 and M3) in 
comparison with other anticholinergics including oxybutynin [40]. 
Studies examining the accumulation of anticholinergic medications in the brain 




concentration levels in the brain compared to the newer anticholinergics [41,42]. 
Preclinical studies on muscarinic receptors with preferential selectivity for the bladder 
over the brain show results favoring Solifenacin and Tolterodine over Oxybutynin [43]. 
Evidence is emerging now that blocking the central M1 receptor has an important role 
in cognitive impairment and consequently, anticholinergic medications with low 
affinity to M3 (lowest selectivity) and high M1 affinity may yield more cognitive 
impairment [44]. 
Pharmacokinetics/drug metabolism changes attributed to aging are important 
considerations in older patients. Slow gastric emptying associated with aging can reduce 
drug bioavailability. Increased free circulating plasma level of the drug can be caused 
by a decrease in Albumin level which is particularly important in Tolterodine 
metabolism [29]. Patients with hepatic dysfunction have altered cytochrome p450 
metabolism which is needed for clearance of some drugs including oxybutynin, 
tolterodine, darifenacin and solifenacin. Reduced renal function is another important 
consideration in an older population especially for renally excreted drugs such as 
Trospium and Tolterodine. Discussion with a medical specialist is recommended 
whenever there are any concerns about drug interactions [12]. 
Third line treatment: PTNS, Sacral Neuromodulation and Intra-Detrusor 
OnabotulinumtoxinA 
The utilization of third line of treatments is limited in Canada. They are only 
considered in patients refractory to behavioral modifications and pharmacotherapy after 
a detailed evaluation to exclude any other causes accounting for lack of response.  
Third-line treatments are associated with potentially significant side effects with long 
term consequences. 
Posterior tibial nerve stimulation (PTNS) effectiveness can be up to 60%, which 
is comparable to oral medication while avoiding the side effects encountered with oral 
medications [45]. The drawback of PTNS arises from the need of a weekly 30-minute 
treatment for 12 weeks then followed by monthly maintenance sessions. It is not 
currently easily accessible in Canada. 
Sacral Neuromodulation (SNS) requires the permanent implantation of a 




imaging, or those who are unable to operate the neurostimulator, poor candidates for 
SNS [46]. Only a few Canadian centers offer this procedure. 
Intra-detrusor onabotulinumtoxinA (BoNT-A) injections (100 U) are 
recommended only for selected patients after failure of the first and second-line 
therapies. Urinary retention requiring clean intermittent self-catheterization 2 weeks 
after BoNT-A injection was 6.2% among women with OAB [47]. It is important before 
starting the treatment that the patient must be willing to return for reassessment to 
measure post void residual (PVR) volume and perform clean intermittent self-
catheterization if needed [48]. PVR > 150 ml increases the risk of urinary tract infection 
especially if acquired for a prolonged duration, and if associated with urogenital atrophy 
as in postmenopausal women [49]. High BMI is also associated with increased risk of 
BoNT-A injection failure [50]. 
Delirium 
Definition 
A state of acute brain failure marked by sudden onset of confusion, a fluctuating 
course, inattention, and often an abnormal level of consciousness [51-53]. Even though 
delirium is extremely common, the diagnosis can be challenging. Hypoactive and quiet 
variants of delirium are more common than purely agitated patients [51,54]. 
Risk factors 
Multifactorial risk factors are commonly involved in delirium and often lie 
outside the central nervous system itself. Common risk factors are divided into 
predisposing factors (e.g. underlying cognitive impairment, multiple comorbidities, 
polypharmacy, impaired sensation, and functional abilities, etc.) and precipitating 
factors (e.g. severe illness, dehydration and electrolyte imbalance, urine retention, 
urinary catheter use, etc.). The sum of both the predisposing factors, as well as 
precipitating factors, are the patient’s risk factors for delirium [55]. 
Diagnosis 
The diagnosis of delirium remains a clinical diagnosis which can be easily 
overlooked. Most cases of delirium (55-80%) are either unrecognized or undocumented 




The current standard diagnostic criteria are the Diagnostic and Statistical Manual 
of Mental Disorders (Fifth edition) (DSM-5) from the American Psychiatric 
Association [59] and the International Statistical Classification of Disease and Related 
Health Problems, Tenth Revision from the World Health Organization (ICD-10) [60]. 
Recognition is based on brief cognitive screening and bed side observation of the key 
features of delirium. The positive predictive value of retrospective administrative 
databases to detect delirium is 71.7% (56.3-83.5%). Negative predictive value is 90.0% 
(88.3-91.4%) [61]. 
The Confusion Assessment Method (CAM) diagnostic algorithm is the briefest 
screening tool for the assessment of delirium [62]. CAM examines the 4 key features of 
delirium: acute change in mental status and fluctuating course; inattention; disorganized 
thinking; and abnormal level of consciousness. The diagnosis with CAM entails the 
presence of the first 2 features plus either the third or fourth. CAM has a sensitivity of 
82% and specificity of 99% provided that the patient has had a prior cognitive 
assessment [63,64]. Unfortunately, this algorithm is only used clinically, and results are 
not explicitly coded in administrative databases. 
Neurotransmitter associated with delirium 
Multiple theories are proposed to explain the pathophysiology of delirium. End 
products of neurochemical pathways can explain the multiple delirium subtypes 
(Hyperactive, Hypoactive, and mixed) [65]. The neurotransmitter hypothesis suggests 
a decline in cholinergic function, excess dopamine, norepinephrine, and glutamate, 
along with changes in serotonin and Gamma-aminobutyric acid may lead to the 
different clinical presentations [65]. 
The potential association between anticholinergics and the risk of delirium has 
been a concern in the recent decades. The association between acetylcholine drug intake 
and neuropsychiatric manifestation has been suggested based on available evidence. 
The most currently accepted theory for the pathogenesis of delirium is the diffuse 
imbalance of cerebral neurotransmission of serotonin, noradrenaline, and dopamine. 
Research is still inconclusive, however, and some studies consider anticholinergic drug 
use as a precipitating factor for delirium [66]. 




Frail older people consume several medications that have anticholinergic side 
effects. According to some studies, it is estimated that more than 30 % of older residents 
in nursing homes take more than two anticholinergic drugs and 5% take more than five 
[67,68]. A relevant anticholinergic cognitive burden score is also found in about one 
half of community-dwelling older adults [69]. 
The toxic effect of these drugs in the aging brain is related to increased 
permeability of the blood-brain barrier with slower metabolism, drug elimination and 
age-related deficit in central cholinesterase transmission [70]. Furthermore, the 
polypharmacy frequently encountered in older populations owing to multiple diseases 
increase the probability of cumulative adverse effect [71]. Despite that, the side effects 
of anticholinergic medications are often considered to be “unavoidable” or wrongly 
attributed to the process of aging itself [72]. 
Institutionalization is an important risk factor for the prescription of 
anticholinergic drugs. Inappropriate drug use is common in hospitalized older adults 
[73,74]. Nursing care home use significantly more anticholinergic drugs than those 
living at home according to the data from some studies [75]. Among hospitalized 
patients who are 65 years and older, the prevalence of anticholinergic prescriptions 
significantly increase during their hospital stay even when comparing them to Geriatric 
Care Units who are more vigilant than other units in the scope of prescribing the 
anticholinergic drugs [76]. In addition, as patients advance towards death in the 
palliative care setting, the use of anticholinergic drugs increase [77]. 
Anticholinergic drug burden evaluation 
Essential anticholinergic drug use, especially amongst the older population, has 
prompted the development of methods to estimate the overall anticholinergic drug 
burden an individual receives [78]. Anticholinergic scales as well as in vitro methods 
have been developed to predict the central and peripheral adverse events associated with 
anticholinergic drug burden to potentially reduce the risk of secondary negative brain 
effect of drug therapy and optimize polypharmacy. However, none of these methods 
have been standardized, nor has an exact definition of a risky drug exposure been 
established [79-82]. 




medications at doses typically administered to older adults. The aim was to help the 
clinician to choose between equally efficacious medications through comparing the 
anticholinergic activity of different drugs within the same therapeutic group. However, 
the in vitro method used to measure serum anticholinergic activity (SAA) faced 
limitations in estimating the overall anticholinergic burden on the human brain. SAA is 
a measure of the peripheral action of the anticholinergic medication rather than central 
one since it does not reflect the drug concentration in the brain [84]. Even if the AA is 
measured in the cerebrospinal fluid, it cannot demonstrate an individual’s sensitivity to 
be cognitively affected by the anticholinergic medication since it does not account for 
the brain’s distribution of the drug. There was no correlation between SAA and 
cholinergic function measured with electroencephalography according to one study 
[85]. Another consideration regarding the SAA is that it does not take into account the 
stress response from an acute illness or make a distinction between medications [86]. 
SAA levels increase during illness and decline during recovery from it [87]. 
The anticholinergic drug scales are expert-based score models developed to 
determine the anticholinergic drug burden. Such scales rank medications on a four-point 
scale depending on their anticholinergic potential, ranging from limited or none (0), 
moderate (1), strong (2), or very strong (3) potential [79,80,82]. The aim is to identify 
drugs with potential adverse effects and propose the withdrawal of these medications. 
The Anticholinergic Drug Scale (ADS) was the initial scale [85], classifying 62 
medications into three levels of anticholinergic potential. SAA was shown to be 
significantly associated with the ADS [88]. Later, this scale had undergone 
modifications and been further extended [89]. 
ADS assesses the cognitive impact of any anticholinergic drug based on literature 
reviews of drugs with anticholinergic potential. The Anticholinergic Risk Scale (ARS), 
on the other hand, assesses the central as well as the peripheral adverse effect of 
anticholinergic drugs [80]. Another scale, the Drug Burden Index (DBI) includes 
anticholinergic drugs as well as sedatives and it differs from the other scales by the fact 
that it is adjusted for dose [81]. In all these scales models, the anticholinergic burden is 
the sum of each anticholinergic drug score assuming that different drugs respect a linear 
additive model. To standardize anticholinergic scales, a recent review has developed a 




Anticholinergics and delirium 
Over 600 compounds have anticholinergic properties, including not only 
prescription medications, but also some of the over-the-counter medications as well as 
some plants [91]. Antimuscarinics would be a more accurate nomenclature to describe 
these compounds as most of them do not inhibit nicotinic receptors. Blockage of the 
central M1 receptor and consequently reducing central acetylcholine is implicated in 
delirium [92]. 
Anticholinergic delirium is a potential complication of antimuscarinic  
compounds. Anticholinergic medications used for the treatment of overactive bladder 
are among those compounds that can lead to anticholinergic delirium. Limited studies 
have investigated the association between anticholinergic medications and delirium 
with the majority being just sporadic case reports. 
Tricyclic antidepressants (TCA), including amitriptyline, are older medications 
historically used for the treatment of depression.  However, they are no longer 
considered the first line of treatment with the development of selective serotonin 
reuptake inhibitors. The central antimuscarinic blockage activity of TCAs can result in 
delirium typically in the elderly [93-95]. However, a case report of a 36-year old 
Caucasian male diagnosed with delirium following administration of 200 mg dose of 
amitriptyline [96] illustrates no age preclusion. 
Antihistamines are another class of medications with antimuscarinic activity, 
which, when taken in higher doses, can result in delirium. A case report describes 
anticholinergic delirium lasting for 6 days in a 14-year old after antihistamine overdose 
ingestion [97]. 
Delirium and hallucinations can be a potential side effect from anticholinergic  
overactive bladder medication. An 80 year-old male with no history of previous 
psychiatric illness was diagnosed with delirium based on ICD-10 after 1 week of daily 
ingestion of 5 mg of Solifenacin each morning [98]. Another case report reported on an 
89 year-old man with no baseline neurological impairment who developed delirium 
after starting Fesoterodine 4 mg once daily for 5 days prior to the onset of delirium, 








Our objective is to measure the differential effects of specific overactive bladder 
medications on delirium. Our hypothesis is that new users of anticholinergics will have 
a higher risk of delirium compared to new users of beta-3 agonists. The need for this 
project emerges from the concern for worsening adverse effects on cognition with the 
use of anticholinergic medications. Limited studies have shown that adults who are 
users of anticholinergics are at higher risk of new onset delirium, and this risk is 
proportional to the cumulative dose of anticholinergic used. Beta-3 agonists provide a 
condition-specific comparison group that also seek medical management for their 
overactive bladder. There is no evidence beta-3 agonists have cognitive effects, and the 






Study Design  
We conducted a retrospective, cohort study utilizing Ontario’s population-based 
data held at ICES. The province of Ontario, Canada has a population exceeding 14 
million and all Ontario residents utilize a single, universal healthcare system. Universal 
medication coverage is provided for those aged > 65 years. Individual patient records 
were linked across the database using a deterministic identification number. The use of 
the database is authorized under the Ontario Personal Health Information Protection 
Act, which does not necessitate approval by the Research Ethics Board, or individual 
patient consent [100]. 
Data Sources 
The following routinely collected data sources were used for the current study:  
the Canadian Institute for Health Information Discharge Abstract  Database (CIHI 
DAD) for admission to acute care hospital in Ontario (provides information on patient 
diagnoses and procedures/interventions); the Canadian Institute for Health Information 
Same Day Surgery (CIHI SDS) (for single day surgeries); the National Ambulatory 
Care Reporting System (NACRS) (for all visits made to hospital emergency rooms and 
ambulatory care centers, including diagnosis, and procedures/interventions) [101,102]; 
the Registered Person Data Base (RPDB) (for vital statistics) [103]; the Ontario Health 
Insurance Plan (OHIP) (for physician billing/diagnostic codes pertaining to patient 
assessments or procedures) [101]; and the Ontario Drug Benefit database (ODB) (for 
publicly funded drug use) [104]. 
Patient Population 
We used the Ontario Drug benefit database to identify users of either OAB 
anticholinergic or beta-3 agonist between 1 January 2016 until 1 March 2020. This 
database has >99% accuracy [104]. The anticholinergics included in this study are 
Oxybutynin, Solifenacin, Tolterodine, Trospium, Darifenacin and Fesoterodine. The 
only beta-3 agonist marketed is Mirabegron (approved for provincial coverage in June 
2015, hence, our start date was set for January 2016). To identify potential differences 
between groups we used matching weights to make the three treatment groups 




ascertain medical comorbidities, 1 year of prior data for healthcare utilization variables, 
and 6 months of prior data to determine if the patient was a current/recent user of 
specific medication classes. 
Inclusion Criteria 
All Ontario residents 66-100 years of age with an oral prescription for one of the 
selected study drugs listed below. We didn’t include patients aged  65-66 years of age 
since ODB starts at the age of 65 years of age and we would not be able to determine if 
a prescription represents the initial use of a medication or a continuation of a medication 
which was prescribed before the age of 65 years of age.  
• Oxybutynin 
• Newer Anticholinergic Medications: Solifenacin, Tolterodine, Trospium, 
Darifenacin and Fesoterodine 
• Beta-3 agonist Medication: Mirabegron 
Exclusion Criteria  
• Missing or invalid ICES Key Number (IKN) 
• Missing age or sex 
• Death on or before the index date (Prescription date) 
• Non-Ontario Residents 
• Prescription for >1 study medication on prescription date  
• A prescription of one or more of the study medications in the past 12 months prior 
to index date 
• Prescription date is between an inpatient admission and discharge date 
• > 1 inpatient hospital discharge for any reason on or in the 2 days prior to the 
prescription date. 
• > 1 Emergency room registration for any reason on or in the two days prior to 
prescription date. 
 




index date will result in poor data quality. We cannot track non- Ontario residents. 
For the prescription part, we excluded patients having more than one study 
medication as it won’t be clear which medication the patient used. Finally, we 
excluded any prescription around hospitalization or emergency room visit to try 
and reduce confounding from any co-existing medical condition that would result 
from temporary use of a prescribed OAB medication. 
Study Outcomes 
Our primary outcome was delirium. Our hypothesis was that the risk of delirium 
would be significantly higher among people taking anticholinergic medications 
compared to our reference group of Beta-3 agonist users. There is no evidence or 
hypothetical mechanism through which beta-3 agonists would affect cognitive function. 
Delirium was defined using validated definition that uses hospital admission 
International Classification of Disease, 10th version (ICD-10) codes, the full list of codes 
related to delirium within the ICD-10 is listed in the appendix. The positive predictive 
value of retrospective administrative database to detect delirium is 71.7% (56.3-83.5%). 
Negative predictive value is 90.0% (88.3-91.4%) [61]. 
       The At-risk period was the study period where we were observing for the study 
outcome. For our primary analysis we started that observation period from the index 
date (prescription date) and then added 30 days. We knew from previous research that 
most people used these medications for only a short period of time, and we felt delirium 
was most likely to occur as an acute complication of anticholinergic therapy. We did a 
secondary analysis considering continuous use of the medications. Continuous usage 
was defined as the time period during which an additional prescription of a medication 
from the same exposure group was filled within 1.5 times the duration of the previous 
prescription. Patients were censored at the end of their last prescription, death, the date 
of a prescription for a medication from another exposure group, or September 30, 2020. 







Matching weights (an extension of propensity score weighting) were used to 
balance the three exposure groups based on the 83 measured indicators of baseline 
health, comorbidity, medication usage, and healthcare utilization [105]. Matching 
weights were generalized to permit comparison between three groups. Propensity scores 
were estimated using multinomial logistic regression, where the model output contained 
predicted probabilities for all three exposure groups. The matching weights were then 
assigned as the minimum of the three predicted probabilities (propensity scores) divided 
by the predicted probability for the treatment they actually received. Between group 
differences were assessed using the average of the standardized differences obtained 
from the three pairwise comparisons of the two anticholinergic groups and the beta-3 
agonist group (a difference of >10% is considered potentially meaningful) [106]. The 
primary analysis was carried out using weighted logistic regression, and odds ratios 
(95% confidence intervals) are reported. For the secondary analysis, a weighted Chi-
squared test was used to compare the risk of the two outcomes between high-dose and 
low-dose users, and weighted Cox proportional hazards regression was used to analyze 
risk of the outcomes during continuous usage.  Hazard ratios and 95% confidence 
intervals obtained from bootstrapping are reported. The relevant assumptions of this 
model were assessed using the Kolmogorov-type supremum test, a non-parametric test 
to confirm whether or not the data is normally distributed in the unweighted model. The 
analytic dataset was complete, aside from the income quintile and rural residence 
variable, which were missing in <0.03%. A two tailed p value <0.05 was considered 








































































1. Missing or invalid IKN  
2. Missing age or sex 
3. Death on or before the index date  
4. Non-Ontario residents 
A prescription for > 1 study medication on the prescription date 
A prescription for > 1 study medication in the past 12 months prior 
to the prescription date. Do not include index date in lookback 
period. 
Prescription date is between an inpatient admission and discharge 
date 
 
> 1 Inpatient hospital discharge for any reason on or in the 2 days 
prior to the prescription date. Include prescription date in lookback 
period. 
> 1 Emergency Room registration for any reason on or in the two 
days prior to the prescription date.  
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We initially identified 95418 new users of the Beta-3 agonist medications, 25336 
new users of Oxybutynin, and 93180 new users of newer anticholinergics (Figures 1). 
After applying both the inclusion and exclusion criteria, we retained 56062 Beta-3 
agonist, 13865 Oxybutynin and 33097 newer anticholinergic drug users (Figure 2).  
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Table (1):  Baseline characteristics pre and post Matching Weights between the 3 groups (Beta-3 agonist, Oxybutynin and Newer 
anticholinergics). Full results of all the baseline characteristics are shown in Appendix 1 
Variable Value 
Pre-weight Post-weight 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
N=56,062 N=13,865 n=33,097 N=56,062 N=13,865 n=33,097 
N SD/% N SD/% N SD/% N SD/% N SD/% N SD/% 
Age 
Mean ± SD 77.16 7.48 76.58 7.5 76.67 7.37 0.05 76.61 3.73 76.58 7.49 76.55 4.81 0.01 
66-69 10259 18.3% 2935 21.2% 6529 19.7% 0.05 2890 21.0% 2924 21.1% 2856 20.6% 0.01 
70-74 13153 23.5% 3340 24.1% 8146 24.6% 0.02 3373 24.5% 3332 24.1% 3435 24.8% 0.01 
75-79 12105 21.6% 2978 21.5% 7206 21.8% 0.00 2843 20.7% 2973 21.5% 2948 21.3% 0.01 
80-84 10053 17.9% 2221 16.0% 5701 17.2% 0.03 2255 16.4% 2220 16.0% 2313 16.7% 0.01 
85-89 6797 12.1% 1537 11.1% 3625 11.0% 0.02 1526 11.1% 1537 11.1% 1479 10.7% 0.01 
90+ 3695 6.6% 854 6.2% 1890 5.7% 0.03 866 6.3% 854 6.2% 814 5.9% 0.01 
Sex 
F 29171 52.0% 9812 70.8% 20338 61.4% 0.26 9653 70.2% 9789 70.7% 9841 71.1% 0.01 
M 26891 48.0% 4053 29.2% 12759 38.6% 0.26 4100 29.8% 4050 29.3% 4004 28.9% 0.01 
Benign Prostatic Hyperplasia   17045 30.4% 1906 13.7% 7510 22.7% 0.27 1943 14.1% 1906 13.8% 1895 13.7% 0.01 
Stroke  2015 3.6% 435 3.1% 1048 3.2% 0.02 442 3.2% 434 3.1% 421 3.0% 0.01 
Congestive Heart Failure  6447 11.5% 1343 9.7% 3654 11.0% 0.04 1364 9.9% 1341 9.7% 1318 9.5% 0.01 
Coronary Artery Disease  16928 30.2% 3487 25.1% 9573 28.9% 0.08 3502 25.5% 3482 25.2% 3448 24.9% 0.01 
Dementia   9750 17.4% 1805 13.0% 4796 14.5% 0.08 1820 13.2% 1803 13.0% 1777 12.8% 0.01 
Hypertension  26278 46.9% 6511 47.0% 16181 48.9% 0.03 6536 47.5% 6502 47.0% 6454 46.6% 0.01 
Atrial Fibrillation  3947 7.0% 795 5.7% 2212 6.7% 0.03 810 5.9% 793 5.7% 769 5.6% 0.01 
Prostatic cancer  6007 10.7% 877 6.3% 2983 9.0% 0.11 884 6.4% 876 6.3% 882 6.4% 0.00 
Parkinson  2818 5.0% 415 3.0% 1039 3.1% 0.07 415 3.0% 415 3.0% 404 2.9% 0.01 
Finasteride  6303 11.2% 615 4.4% 2539 7.7% 0.17 632 4.6% 615 4.4% 604 4.4% 0.01 
Prostate specific alpha blocker  13472 24.0% 1424 10.3% 5477 16.5% 0.25 1456 10.6% 1424 10.3% 1389 10.0% 0.01 
Urology clinic visit count Mean ± SD 1.27 2.45 0.57 1.96 1.05 2.34 0.21 0.59 1.04 0.57 1.96 0.57 1.26 0.01 
Trans-urethral resection of prostate  1769 3.2% 117 0.8% 720 2.2% 0.12 119 0.9% 117 0.8% 117 0.8% 0.01 
Prostatic specific antigen test  9409 16.8% 1094 7.9% 4091 12.4% 0.18 1124 8.2% 1093 7.9% 1068 7.7% 0.01 
Bladder scan  8978 16.0% 688 5.0% 4265 12.9% 0.24 719 5.2% 688 5.0% 688 5.0% 0.01 
Post-void residual  8296 14.8% 698 5.0% 3589 10.8% 0.22 706 5.1% 698 5.0% 707 5.1% 0.00 
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To identify potential differences between groups, we measured 83 baseline 
characteristics (full base line characteristics pre- and post-matching are provided in 
Appendix (1-5). Pre-weight, the baseline characteristics were generally similar between 
the three groups (Table 1); however there were relevant differences in standardized 
differences in gender and multiple urological variables such as the number of urology 
clinics visits, Previous Benign prostatic hyperplasia (BPH), Prostatic cancer, 
Transurethral resection of prostate (TURP), Prostate specific antigen (PSA) tests, 
bladder scan and post-void residual urine volume. Some medications also showed a 
standard difference such as 5-alpha reductase inhibitors as well as prostate specific 
alpha blocker.  
After matching, we retained 13752 beta-3 agonist users ,13839 oxybutynin drug 
users, 13845 Newer anticholinergic drug users and (Table 2). After matching, the 
previous difference in baseline characteristics were no longer significant.  
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Table (2): Delirium risk at 30 days 
Outcome Exposure 
Unweighted sample Weighted sample 











Oxybutynin 49 / 13865 0.35% 49/ 13839 0.35% 1.28 0.84 1.96 0.25 
Newer OAB 
Anticholinergics 
93 / 33097 0.28% 35/ 13845 0.25% 0.92 0.58 1.46 0.73 
 
Table (3): Delirium risk during continuous usage 





rate per 100 
person-years 









Oxybutynin 124/13,839 0.9% 3,475 3.56 
+0.68 per 100 
person-years 
0.03 1.39 1.18 0.96 1.44 
Newer OAB 
Anticholinergics 
263/13,845 1.9% 8.020 3.28 
+0.41 per 100 
person-years 
0.11 0.92 1.13 1.02 1.26 
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The primary outcome was to assess the risk of delirium among the anticholinergic 
drug users (Oxybutynin, Newer anticholinergics) compared to beta-3 agonist during our 
observational period which was set to be 30 days from index date. There was no 
statistically significant difference at 30 days between Oxybutynin drug users compared 
to beta-3 agonist drug users (odds ratio 1.28, 95% CI 0.84-1.96 and p-value 0.25) also 
no statistically significant difference was found between the newer anticholinergic drug 
users group compared to beta-3 agonist drug users (odds ratio 0.92,95% CI 0.58-1.46 
and p-value 0.73) (Table 2). 
Our secondary analysis was to consider the risk of delirium during the period of 
continuous usage. The median interquartile range (IQR) duration of continuous usage 
was 113 (30-380) days for Beta-3 agonist, 30 (28-72) days for Oxybutynin, and 62 (30-
239) days for the newer anticholinergics. When looking at the outcome of delirium 
during continuous use, the cox proportional analysis showed a slight increase in risk of 
delirium in the Newer Anticholinergic group compared to the Beta-3 agonist (HR 1.13, 






In this study we examined whether using OAB anticholinergic medications are 
associated with an increased risk of delirium in an elderly population. Cerebral 
neurotransmitter imbalance is the most accepted theory for the pathogenesis of delirium 
and the potential association between anticholinergics and the risk of delirium has been 
a concern in recent years [66].  
According to Ontario Drug Benefit program which covers medications for 
individuals above 65 years old, a trial of Oxybutynin is still required as first line treatment 
of OAB [107]. This was not consistent with the findings retrieved from the data base during 
our study period. The Beta-3 agonist was the most prescribed medication followed by 
newer anticholinergics and lastly Oxybutynin. This change in prescription pattern may 
reflect physician knowledge that Oxybutynin has more potential cognitive risks, and the 
highest risk of the adverse effects as dry mouth and constipation.  
The inclination of the majority of Urologist to prescribe Beta-3 agonist as an 
initial treatment for patients presenting with OAB was reflected in pre-weight standard 
difference (Table 1) in the variables specific for urology as benign prostatic hyperplasia, 
prostatic cancer, 5 alpha reductase inhibitors, Prostatic specific alpha blocker, bladder 
scan, post-void residual and the number of visits to urology clinic. On the contrary, a 
standard difference might have been expected to be significant between beta-3 agonist 
and anticholinergics especially in patients with hypertension and underlying cardiac 
condition since beta-3 agonist might affect blood pressure, however this was not the 
case. In clinical practice, even with pre-existing hypertension or cardiac condition, 
physicians are not hesitant to prescribe beta-3 agonist and they often just instruct 
patients to monitor their blood pressure after initial use. This is in keeping with recent 
population based cardiac safety data [107]. 
In contrast to previous literature on the topic of risk of dementia associated with 
the anticholinergic use, we expected that there would be a significant standard 
difference in the pre-weight group in patients with pre-existing dementia (Table 1), but 
this was not observed; however, there was an increased proportion of patients treated 
with beta-3 agonists compared to anticholinergics. The prevalence of dementia among 
the OAB drug users was higher than prevalence reported by public health agency of 
Canada, the prevalence is 5.6 % among males and 8.3 % among females. According to 
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our study results, 13.0% of Oxybutynin and 14.5% of newer anticholinergics drug users 
had underlying dementia in the pre-weight base line characteristics (Table 1). This 
higher percentage can be explained by the higher incidence of OAB symptoms among 
people with dementia [100]. 
 Parkinson disease is another point of interest as anticholinergics play a role in 
improving the disease manifestation, yet no significant standard difference was evident 
towards prescribing anticholinergics in favor of beta-3 agonist.  
We are not aware of any previous study that has investigated the risk of delirium 
following the usage of OAB anticholinergic medication except for some case reports. 
This is the first population-based study. We found that in the first 30 days after initiating 
oxybutynin or one of the newer OAB anticholinergics, there was no significant 
increased risk of delirium. This suggests that the risk of these events is low with a 30-
day trial of anticholinergic medications (which is relevant to most patients given the 
limited long-term use of these medications [108]. When considering the period of 
continuous use of these medications, newer anticholinergics had a slightly increased  
risk of delirium (HR 1.13). These results are statistically significant; however, the 
relative difference is small. It is important to note that the point estimate for newer 
anticholinergics and delirium was OR 0.92 in the 30-day analysis, and HR 1.13 in the 
continuous use analysis, suggesting the risk for delirium may increase with continued 
use. The point estimate for oxybutynin is similar between the two analyses. This study 
showed no statistically significant risk of delirium between Oxybutynin and newer 
anticholinergics compared to the control group of beta-3 agonist users during the 30 
days observational window. The differential effects of oxybutynin versus newer 
anticholinergics may be due to more significant central nervous system effects that 
specifically mediate delirium [109,110], and longer persistence with newer 
anticholinergic medications may have increased our statistical power for the detection 
of the increased risk of delirium. Our study supports the use of OAB beta-3 agonists to 
avoid the increased risk of delirium that is associated with OAB anticholinergic 
medications.  
Anticholinergic drug burden might be the underlying factor that causes patients 
to develop delirium following administration of OAB anticholinergic medication. For 
example, the case report of an 89 year-old with multiple underlying co-morbid  
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conditions including stage 4 chronic kidney disease developed delirium following 
Fesoterodine; this might be the result of anticholinergic drug overload [99]. Other case 
reports described delirium that developed following antihistamine overdose in a 14 year 
old healthy female [97], or delirium following ingestion of a large dose amitriptyline in 
a healthy 36 year-old [96].  
Thus, the continuous use of anticholinergics and the dosage might be the risk 
factor for the development of delirium, and this is consistent with our secondary 
findings which showed a slight increased incidence of delirium associated with 
continuous use of newer anticholinergic medications. 
Anticholinergic medications inhibit the release of acetylcholine, and this may impair 
attention, sleep, and memory processes that rely on this neurotransmitter. Much of the 
previous study on this topic has used measures of anticholinergic load to measure the risk 
of delirium. Unfortunately, these scales have significant variability [111], and in a 
systematic review the association between delirium and anticholinergics varied based on 
the method used to calculate anticholinergic load [112]. This likely contributes to some of 
the variability in the literature, and accounts for clinical studies supporting a lack of 
association between anticholinergic medications and delirium [113].  
The present study has some important limitations. We relied on filled 
prescriptions, which cannot account for the compliance of the patients. We used the 
ICD-10 coding for delirium to search the ICES database which has a positive predictive 
value of 71.7% which give us moderate confidence of the precise diagnoses of delirium 
[61]. However, the same definition was used for all groups, therefore we would not 
expect there to be differential misclassification across the 3 groups. This means that 
while this may have reduced the absolute rate of delirium, the relative difference (ie the 
hazard ratio) between the groups should still be accurate. Certain non-prescription 
medications have anticholinergic activity such as antihistamine use, which cannot be 
measured in our study, but can contribute to a patient’s anticholinergic drug burden, 
however, we do not believe it to be a significant confounder as it would likely be similar 
among the 3 groups. 
We did not measure some gynecological variables in the pre-weight baseline 
characteristics which can be a contributing factor for the higher incidence of OAB 
among females (61.4%) when compared to males (38.6%) (Table 1). Again, these 
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variables should not be differentially distributed based on the type of OAB medication 
initiated and are less relevant as most patients (approximately 90%) had not seen a 
gynecologist in the year prior to the start of OAB medications (Appendix 5). 
The present study is an important addition to the literature for two main reasons. 
First, it reflects the change in prescription pattern that has been occurring in the last 5 
years with more utilization of newer OAB medications at the expense of the older ones. 
Second, it shows a small but increased risk of delirium associated with newer 
anticholinergics during continuous use. 
In conclusion, our study showed that the use of anticholinergic medications 
among patients with OAB was not associated with an increased risk of delirium 
compared to beta-3 agonist users in the 30 days duration; however, the risk is slightly 
increased with increased prescription duration. We believe that anticholinergics should 
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Appendix (1): Full results of all the baseline characteristics (1) 
Variable Value 
Pre-weight Post-weight 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
N=56,062 N=13,865 n=33,097 N=56,062 N=13,865 n=33,097 
N % N % N % N % N % N % 
Year of cohort 
entry 
2016 11639 20.8% 3590 25.9% 9568 28.9% 0.13 3516 25.6% 3581 25.9% 3628 26.2% 0.01 
2017 13142 23.4% 3688 26.6% 8249 24.9% 0.05 3637 26.4% 3683 26.6% 3737 27.0% 0.01 
2018 14456 25.8% 2848 20.5% 7847 23.7% 0.09 2833 20.6% 2847 20.6% 2846 20.6% 0.00 
2019 14533 25.9% 3276 23.6% 6509 19.7% 0.10 3293 23.9% 3267 23.6% 3198 23.1% 0.01 
2020 2292 4.1% 463 3.3% 924 2.8% 0.05 474 3.4% 462 3.3% 436 3.1% 0.01 
Rural 
Missing 125 0.2% 26 0.2% 81 0.2% 0.00 30 0.2% 26 0.2% 31 0.2% 0.00 
N 49837 88.9% 11625 83.8% 29206 88.2% 0.10 11496 83.6% 11619 84.0% 11626 84.0% 0.01 
Y 6100 10.9% 2214 16.0% 3810 11.5% 0.10 2227 16.2% 2194 15.9% 2189 15.8% 0.01 
Incquint 
Missing 137 0.2% 39 0.3% 91 0.3% 0.01 32 0.2% 39 0.3% 36 0.3% 0.01 
1 11380 20.3% 3179 22.9% 7260 21.9% 0.04 3173 23.1% 3170 22.9% 3138 22.7% 0.00 
2 11826 21.1% 3023 21.8% 7210 21.8% 0.01 3002 21.8% 3016 21.8% 3018 21.8% 0.00 
3 10855 19.4% 2726 19.7% 6587 19.9% 0.01 2711 19.7% 2722 19.7% 2723 19.7% 0.00 
4 10443 18.6% 2443 17.6% 5916 17.9% 0.02 2407 17.5% 2440 17.6% 2455 17.7% 0.00 
5 11421 20.4% 2455 17.7% 6033 18.2% 0.05 2427 17.7% 2452 17.7% 2475 17.9% 0.01 
Ltc 
0 54589 97.4% 13473 97.2% 32314 97.6% 0.02 13363 97.2% 13449 97.2% 13456 97.2% 0.00 
1 1473 2.6% 392 2.8% 783 2.4% 0.02 389 2.8% 390 2.8% 389 2.8% 0.00 
Stroke   2015 3.6% 435 3.1% 1048 3.2% 0.02 442 3.2% 434 3.1% 421 3.0% 0.01 
Chf   6447 11.5% 1343 9.7% 3654 11.0% 0.04 1364 9.9% 1341 9.7% 1318 9.5% 0.01 
Cad   16928 30.2% 3487 25.1% 9573 28.9% 0.08 3502 25.5% 3482 25.2% 3448 24.9% 0.01 
Depression   3669 6.5% 954 6.9% 2109 6.4% 0.01 940 6.8% 947 6.8% 952 6.9% 0.00 
Cancer   5982 10.7% 1471 10.6% 3502 10.6% 0.00 1473 10.7% 1466 10.6% 1463 10.6% 0.00 
Seizure   464 0.8% 103 0.7% 222 0.7% 0.01 105 0.8% 102 0.7% 98 0.7% 0.01 
Charl 
Mean ± SD 0.5 1.18 0.45 1.17 0.47 1.17 0.03 0.45 0.56 0.44 1.17 0.44 0.74 0.01 
Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0)  0 (0-0) 0 (0-0) 0 (0-0)  
0 43821 78.2% 11249 81.1% 26284 79.4% 0.05 11045 80.3% 11232 81.2% 11185 80.8% 0.01 
1 4372 7.8% 946 6.8% 2463 7.4% 0.03 1005 7.3% 943 6.8% 1014 7.3% 0.01 
2 4020 7.2% 842 6.1% 2186 6.6% 0.03 852 6.2% 840 6.1% 814 5.9% 0.01 
3+ 3849 6.9% 828 6.0% 2164 6.5% 0.03 851 6.2% 823 5.9% 833 6.0% 0.01 
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Appendix (2): Full results of all the baseline characteristics (2) 
Variable 
Pre-weight Post-weight 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
N=56,062 N=13,865 n=33,097 N=56,062 N=13,865 n=33,097 
N % N % N % N % N % N % 
Cranialtrauma 3115 5.6% 664 4.8% 1665 5.0% 0.03 671 4.9% 662 4.8% 644 4.7% 0.00 
Encephalitis 60 0.1% 10 0.1% 34 0.1% 0.00 10 0.1% 10 0.1% 10 0.1% 0.00 
Ms 263 0.5% 94 0.7% 153 0.5% 0.02 91 0.7% 92 0.7% 93 0.7% 0.00 
Sci 55 0.1% 12 0.1% 48 0.1% 0.00 12 0.1% 12 0.1% 12 0.1% 0.00 
Aur  4173 7.4% 652 4.7% 2020 6.1% 0.07 680 4.9% 648 4.7% 640 4.6% 0.01 
Drugabuse 255 0.5% 74 0.5% 114 0.3% 0.02 71 0.5% 70 0.5% 71 0.5% 0.00 
Schizo 242 0.4% 84 0.6% 149 0.5% 0.02 84 0.6% 81 0.6% 82 0.6% 0.00 
Bipolar 197 0.4% 55 0.4% 138 0.4% 0.00 56 0.4% 54 0.4% 52 0.4% 0.00 
Anxiety 1944 3.5% 527 3.8% 1113 3.4% 0.02 528 3.8% 520 3.8% 514 3.7% 0.01 
Personality 44 0.1% 20 0.1% 33 0.1% 0.00 19 0.1% 18 0.1% 19 0.1% 0.00 
Priormh 2233 4.0% 607 4.4% 1301 3.9% 0.02 607 4.4% 600 4.3% 596 4.3% 0.00 
Abt 21389 38.2% 4759 34.3% 12390 37.4% 0.05 4751 34.6% 4750 34.3% 4749 34.3% 0.01 
Anc 2540 4.5% 721 5.2% 1541 4.7% 0.02 728 5.3% 716 5.2% 710 5.1% 0.00 
Aoa 12274 21.9% 3050 22.0% 7789 23.5% 0.03 3042 22.1% 3044 22.0% 3046 22.0% 0.00 
Baa 8386 15.0% 2152 15.5% 5019 15.2% 0.01 2129 15.5% 2145 15.5% 2152 15.5% 0.00 
Bbl 13670 24.4% 3214 23.2% 8383 25.3% 0.03 3240 23.6% 3208 23.2% 3165 22.9% 0.01 
Bez 7863 14.0% 2089 15.1% 4783 14.5% 0.02 2070 15.1% 2080 15.0% 2095 15.1% 0.00 
Ccb 13064 23.3% 3286 23.7% 8186 24.7% 0.02 3313 24.1% 3281 23.7% 3249 23.5% 0.01 
Ccs 5935 10.6% 1464 10.6% 3371 10.2% 0.01 1470 10.7% 1458 10.5% 1460 10.5% 0.01 
Cho 697 1.2% 81 0.6% 275 0.8% 0.04 81 0.6% 81 0.6% 80 0.6% 0.00 
Dep 6076 10.8% 1661 12.0% 3451 10.4% 0.03 1635 11.9% 1651 11.9% 1661 12.0% 0.00 
Ksd 1677 3.0% 456 3.3% 982 3.0% 0.01 458 3.3% 454 3.3% 455 3.3% 0.00 
Mood 843 1.5% 189 1.4% 444 1.3% 0.01 195 1.4% 188 1.4% 183 1.3% 0.01 
Narc 11639 20.8% 3066 22.1% 6775 20.5% 0.03 3058 22.2% 3049 22.0% 3043 22.0% 0.00 
Nab 1455 2.6% 335 2.4% 826 2.5% 0.01 337 2.5% 334 2.4% 336 2.4% 0.01 
Nsd 10711 19.1% 2798 20.2% 6641 20.1% 0.02 2797 20.3% 2791 20.2% 2770 20.0% 0.00 
Oap 499 0.9% 175 1.3% 285 0.9% 0.03 174 1.3% 167 1.2% 166 1.2% 0.01 
Otd 6835 12.2% 1824 13.2% 3913 11.8% 0.03 1819 13.2% 1816 13.1% 1812 13.1% 0.00 
Pab 13472 24.0% 1424 10.3% 5477 16.5% 0.25 1456 10.6% 1424 10.3% 1389 10.0% 0.01 
Park 2745 4.9% 464 3.3% 1100 3.3% 0.05 467 3.4% 463 3.3% 451 3.3% 0.01 
Sce 68 0.1% 24 0.2% 42 0.1% 0.02 23 0.2% 23 0.2% 22 0.2% 0.00 
Sta 15280 27.3% 3427 24.7% 9228 27.9% 0.05 3429 24.9% 3424 24.7% 3410 24.6% 0.00 
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Appendix (3): Full results of all the baseline characteristics (3) 
Variable Value 
Pre-weight Post-weight 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
N=56,062 N=13,865 n=33,097 N=56,062 N=13,865 n=33,097 
N % N % N % N % N % N % 
Ndins  
Mean ± SD 9.28 5.95 8.89 6.15 9.03 6.02 0.04 8.95 2.98 8.88 6.13 8.84 3.97 0.02 
Median (IQR) 8 (5-12) 8 (4-12) 8 (5-12)  8 (5-12) 8 (4-12) 8 (4-12)  
0 1026 1.8% 382 2.8% 857 2.6% 0.04 328 2.4% 382 2.8% 426 3.1% 0.03 
1-4 10981 19.6% 3094 22.3% 6881 20.8% 0.05 2983 21.7% 3091 22.3% 3095 22.4% 0.01 
5-8 16984 30.3% 4253 30.7% 10008 30.2% 0.01 4199 30.5% 4249 30.7% 4148 30.0% 0.01 
9-12 13279 23.7% 2959 21.3% 7578 22.9% 0.04 3050 22.2% 2954 21.3% 3036 21.9% 0.01 
13-16 7434 13.3% 1678 12.1% 4172 12.6% 0.03 1707 12.4% 1673 12.1% 1654 11.9% 0.01 
17+ 6358 11.3% 1499 10.8% 3601 10.9% 0.01 1485 10.8% 1490 10.8% 1486 10.7% 0.00 
hospcount 
Mean ± SD 0.3 0.71 0.26 0.69 0.28 0.69 0.04 0.26 0.34 0.26 0.69 0.26 0.43 0.00 
Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0)  0 (0-0) 0 (0-0) 0 (0-0)  
0 44435 79.3% 11451 82.6% 26594 80.4% 0.06 11265 81.9% 11433 82.6% 11356 82.0% 0.01 
1 8311 14.8% 1697 12.2% 4666 14.1% 0.05 1769 12.9% 1692 12.2% 1795 13.0% 0.01 
2 2183 3.9% 445 3.2% 1200 3.6% 0.03 467 3.4% 443 3.2% 456 3.3% 0.01 
3+ 1133 2.0% 272 2.0% 637 1.9% 0.01 251 1.8% 270 2.0% 239 1.7% 0.01 
edcount 
Mean ± SD 0.95 1.7 0.88 1.76 0.91 1.7 0.03 0.9 0.87 0.88 1.71 0.87 1.1 0.02 
Median (IQR) 0 (0-1) 0 (0-1) 0 (0-1)  0 (0-1) 0 (0-1) 0 (0-1)  
0 31897 56.9% 8295 59.8% 19363 58.5% 0.04 8110 59.0% 8285 59.9% 8294 59.9% 0.01 
1 11969 21.3% 2807 20.2% 7002 21.2% 0.02 2837 20.6% 2803 20.3% 2879 20.8% 0.01 
2 5666 10.1% 1298 9.4% 3118 9.4% 0.01 1327 9.6% 1295 9.4% 1248 9.0% 0.01 
3+ 6530 11.6% 1465 10.6% 3614 10.9% 0.02 1478 10.7% 1456 10.5% 1424 10.3% 0.01 
gpmhcount 
Mean ± SD 0.32 1.18 0.32 1.44 0.32 1.26 0.00 0.32 0.58 0.32 1.44 0.32 0.79 0.00 
Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0)  0 (0-0) 0 (0-0) 0 (0-0)  
0 47592 84.9% 11833 85.3% 28157 85.1% 0.01 11674 84.9% 11812 85.4% 11771 85.0% 0.01 
1 4865 8.7% 1150 8.3% 2834 8.6% 0.01 1198 8.7% 1148 8.3% 1194 8.6% 0.01 
2 1752 3.1% 431 3.1% 976 2.9% 0.01 427 3.1% 430 3.1% 412 3.0% 0.01 
3+ 1853 3.3% 451 3.3% 1130 3.4% 0.01 453 3.3% 449 3.2% 469 3.4% 0.01 
gpcount 
Mean ± SD 10.06 10.6 9.67 10.4 9.87 10.34 0.03 9.76 5.35 9.66 10.38 9.61 6.66 0.01 
Median (IQR) 7 (4-12) 7 (4-12) 7 (4-12)  7 (4-12) 7 (4-12) 7 (4-12)  
0 1508 2.7% 500 3.6% 1017 3.1% 0.03 419 3.0% 499 3.6% 473 3.4% 0.02 
1-3 8993 16.0% 2543 18.3% 5630 17.0% 0.04 2400 17.4% 2540 18.4% 2535 18.3% 0.02 
4-6 13969 24.9% 3450 24.9% 8183 24.7% 0.00 3544 25.8% 3446 24.9% 3458 25.0% 0.01 
7-9 10980 19.6% 2621 18.9% 6340 19.2% 0.01 2647 19.2% 2618 18.9% 2610 18.8% 0.01 
10+ 20612 36.8% 4751 34.3% 11927 36.0% 0.04 4743 34.5% 4737 34.2% 4770 34.5% 0.01 
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Appendix (4): Full results of all the baseline characteristics (4) 
Variable Value 
Pre-weight Post-weight 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
N=56,062 N=13,865 n=33,097 N=56,062 N=13,865 n=33,097 
N % N % N % N % N % N % 
Neurcount 
Mean ± SD 0.29 1.19 0.21 1.15 0.22 1.2 0.05 0.21 0.51 0.21 1.14 0.21 0.78 0.00 
Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) 
 
0 (0-0) 0 (0-0) 0 (0-0) 
 
0 49240 87.8% 12609 90.9% 29851 90.2% 0.07 12440 90.5% 12586 90.9% 12608 91.1% 0.01 
1 3120 5.6% 629 4.5% 1604 4.8% 0.03 674 4.9% 628 4.5% 626 4.5% 0.01 
2 1812 3.2% 318 2.3% 813 2.5% 0.04 332 2.4% 316 2.3% 305 2.2% 0.01 
3+ 1890 3.4% 309 2.2% 829 2.5% 0.05 307 2.2% 309 2.2% 305 2.2% 0.00 
Psycount 
Mean ± SD 0.27 2.77 0.23 2.53 0.24 2.84 0.01 0.23 1.23 0.23 2.53 0.23 1.7 0.00 
Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) 
 
0 (0-0) 0 (0-0) 0 (0-0) 
 
0 53653 95.7% 13338 96.2% 31882 96.3% 0.02 13204 96.0% 13315 96.2% 13346 96.4% 0.01 
1 811 1.4% 152 1.1% 329 1.0% 0.03 188 1.4% 152 1.1% 137 1.0% 0.03 
2 403 0.7% 81 0.6% 212 0.6% 0.01 96 0.7% 80 0.6% 91 0.7% 0.01 
3+ 1195 2.1% 294 2.1% 674 2.0% 0.01 264 1.9% 292 2.1% 271 2.0% 0.01 
Urocount 
Mean ± SD 1.27 2.45 0.57 1.96 1.05 2.34 0.21 0.59 1.04 0.57 1.96 0.57 1.26 0.01 
Median (IQR) 0 (0-2) 0 (0-0) 0 (0-1) 
 
0 (0-0) 0 (0-0) 0 (0-0) 
 
0 31779 56.7% 11639 83.9% 22017 66.5% 0.41 11499 83.6% 11613 83.9% 11616 83.9% 0.01 
1 9363 16.7% 690 5.0% 3974 12.0% 0.25 698 5.1% 690 5.0% 691 5.0% 0.00 
2 5762 10.3% 518 3.7% 2571 7.8% 0.18 525 3.8% 518 3.7% 515 3.7% 0.01 







Appendix (5): Full results of all the baseline characteristics (5) 
Variable Value 
Pre-weight Post-weight 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
B3 Unexposed ACoxy Exposed Acnew Exposed 
Stan. 
Diff. 
N=56,062 N=13,865 n=33,097 N=56,062 N=13,865 n=33,097 
N % N % N % N % N % N % 
Gyncount  
Mean ± SD 0.23 0.98 0.21 1.02 0.28 1.08 0.05 0.22 0.41 0.21 1.02 0.21 0.54 0.01 
Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0)  0 (0-0) 0 (0-0) 0 (0-0)  
0 50752 90.5% 12711 91.7% 29358 88.7% 0.07 12339 89.7% 12685 91.7% 12429 89.8% 0.05 
1 2421 4.3% 514 3.7% 1740 5.3% 0.05 718 5.2% 513 3.7% 747 5.4% 0.05 
2 1147 2.0% 253 1.8% 778 2.4% 0.03 322 2.3% 253 1.8% 300 2.2% 0.03 
3+ 1742 3.1% 387 2.8% 1221 3.7% 0.03 373 2.7% 387 2.8% 370 2.7% 0.01 
Carcath   940 1.7% 198 1.4% 563 1.7% 0.01 197 1.4% 198 1.4% 202 1.5% 0.01 
Echo   12513 22.3% 2622 18.9% 6878 20.8% 0.06 2633 19.1% 2617 18.9% 2580 18.6% 0.01 
Holter   5805 10.4% 1124 8.1% 3122 9.4% 0.05 1135 8.3% 1123 8.1% 1106 8.0% 0.01 
Stress   7789 13.9% 1610 11.6% 4301 13.0% 0.05 1626 11.8% 1609 11.6% 1598 11.5% 0.01 
Cthead   8021 14.3% 1750 12.6% 4313 13.0% 0.03 1753 12.7% 1745 12.6% 1738 12.6% 0.00 
Mrihead   3019 5.4% 546 3.9% 1439 4.3% 0.05 550 4.0% 545 3.9% 534 3.9% 0.01 
Chestxray   20966 37.4% 4816 34.7% 11969 36.2% 0.04 4832 35.1% 4803 34.7% 4761 34.4% 0.01 
Urineculture   28419 50.7% 6163 44.5% 15965 48.2% 0.08 6182 45.0% 6156 44.5% 6116 44.2% 0.01 
Turp   1769 3.2% 117 0.8% 720 2.2% 0.12 119 0.9% 117 0.8% 117 0.8% 0.01 
Psatest   9409 16.8% 1094 7.9% 4091 12.4% 0.18 1124 8.2% 1093 7.9% 1068 7.7% 0.01 
Trusbiopsy   744 1.3% 160 1.2% 475 1.4% 0.01 159 1.2% 160 1.2% 163 1.2% 0.00 
Bladderscan   8978 16.0% 688 5.0% 4265 12.9% 0.24 719 5.2% 688 5.0% 688 5.0% 0.01 
Postvoid   8296 14.8% 698 5.0% 3589 10.8% 0.22 706 5.1% 698 5.0% 707 5.1% 0.00 
Stressincontsurg   277 0.5% 28 0.2% 154 0.5% 0.03 28 0.2% 28 0.2% 28 0.2% 0.00 
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Appendix (6) Delirium Codes 
ICD-10 version  
F05  Delirium due to known physiological condition  
F10121  Alcohol abuse with intoxication delirium  
F10221  Alcohol dependence with intoxication delirium  
F10231  Alcohol dependence with withdrawal delirium  
F10921  Alcohol use, unspecified with intoxication delirium  
F11121  Opioid abuse with intoxication delirium  
F11221  Opioid dependence with intoxication delirium  
F11921  Opioid use, unspecified with intoxication delirium  
F12121  Cannabis abuse with intoxication delirium  
F12221  Cannabis dependence with intoxication delirium  
F12921  Cannabis use, unspecified with intoxication delirium  
F13121  Sedative, hypnotic or anxiolytic abuse with intoxication delirium  
F13221  Sedative, hypnotic or anxiolytic dependence with intoxication delirium  
F13231  Sedative, hypnotic or anxiolytic dependence with withdrawal delirium  
F13921  Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium  
F13931  Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium  
F14121  Cocaine abuse with intoxication with delirium  
F14221  Cocaine dependence with intoxication delirium  
F14921  Cocaine use, unspecified with intoxication delirium  
F15121  Other stimulant abuse with intoxication delirium  
F15221  Other stimulant dependence with intoxication delirium  
F15921  Other stimulant use, unspecified with intoxication delirium  
F16121  Hallucinogen abuse with intoxication with delirium  
F16221  Hallucinogen dependence with intoxication with delirium  
F16921  Hallucinogen use, unspecified with intoxication with delirium  
F18121  Inhalant abuse with intoxication delirium  
F18221  Inhalant dependence with intoxication delirium  
F18921  Inhalant use, unspecified with intoxication with delirium  
F19121  Other psychoactive substance abuse with intoxication delirium  
F19221  Other psychoactive substance dependence with intoxication delirium  
F19231  Other psychoactive substance dependence with withdrawal delirium  
F19921  Other psychoactive substance use, unspecified with intoxication with delirium  
F19931  Other psychoactive substance use, unspecified with withdrawal delirium  
A812  Progressive multifocal leukoencephalopathy  
E512  Wernicke's encephalopathy  
G0430  Acute necrotizing hemorrhagic encephalopathy, unspecified  
G0431  Post-infectious acute necrotizing hemorrhagic encephalopathy  
G0432  Post-immunization acute necrotizing hemorrhagic encephalopathy  
G0439  Other acute necrotizing hemorrhagic encephalopathy  
G92  Toxic encephalopathy  
G9340  Encephalopathy, unspecified  
G9341  Metabolic encephalopathy  
G9349  Other encephalopathy  
I673  Progressive vascular leukoencephalopathy  
I674  Hypertensive encephalopathy  
I6783  Posterior reversible encephalopathy syndrome  
J1081  Influenza due to other identified influenza virus with encephalopathy  
J1181  Influenza due to unidentified influenza virus with encephalopathy  
P9160  Hypoxic ischemic encephalopathy, unspecified  
P9161  Mild hypoxic ischemic encephalopathy  
P9162  Moderate hypoxic ischemic encephalopathy 






























My career aim is to work as a Uro-gynecologist in a Canadian academic center that provides 
access to a wide range of clinical work, research, and teaching activities. I am very passionate 
about providing the best care for my patients through up-to-date clinical knowledge, working 
closely in a multi-disciplinary team and communicating with different referring departments. 
Performing good patient communication and offering all option of care so my patients can 




September 2020 – PRESENT    
Master of Surgery   
Western University, London, ON, Canada   
Urology/ Uro-gynecology departments, Victoria Hospital  My 
duties include:   
• Attending lectures required for fulfilling the Master degree  
• Preparing the thesis for defence  
• Reviewing up to date guidelines and literature review about current 
recommended      treatment   
                   Thesis Defence Scheduled for August 2021  
  
September 2016- PRESENT  
 





JULY 2018 – JUNE 2020   
CLINICAL FELLOW IN Urogynecology   
Department of Obstetrics and Gynecology, Schulich School of Medicine and Dentistry                            
Western University, London, ON, Canada  My 
duties included:   
• Primary Surgeon/ Primary assistant in Urogynecology operative list 3 days/week.  
• Outpatient Urogynecology clinic 2 days/ week.  
• Rotation with Urology, Colorectal and minimally invasive gynecological surgery.  
• Review and discuss challenging cases with consultants and residents  
• Participate in Journal club and present in urogynecology Journal club days.   
• Resident and Medical student teaching.   
• Participate in urogynecology grand rounds.   
   
JAN 2018 – April 2018  
OBSERVER IN Urogynecology    
Department of Obstetrics and Gynecology, Schulich School of Medicine and Dentistry                           
Western University, London, ON, Canada  
  
August 2014 – September 2016  
Demonstrator/ Obstetrics and Gynecology Specialist  
 Alexandria University Faculty of Medicine   
 Obstetrics and Gynecology Department, El Shatby Maternity Hospital 
Department of Obstetrics and Gynecology, Alexandria University, Egypt  My 
duties included:  
• On Call specialist managing complicated Obstetrics and 
Gynecology cases.  
• Independent specialist at University Hospital  
• Supervising and teaching residents  
• Grand rounds supervision and presentation  
• Teaching undergraduate medical students  
  
June 2011-August 2014  
Obstetrics and Gynecology resident  
  
MAR 2011 – JUN 2011   
GENERAL PRACTITIONER   
Directorate of Health Affairs, Alexandria, Egypt   
   
MAR 2010 – FEB 2011   
HOUSE OFFICER    
Faculty of Medicine, Alexandria University Hospital, Egypt   
    
  
EDUCATION   
  




May 2015: Master Degree in Obstetrics and Gynecology  
  
JULY 2003 – JUNE 2010   
BACHELOR OF MEDICINE AND SURGERY: MBBCH   
University of Alexandria, Faculty of Medicine, Alexandria, Egypt   
  
 May 2010 - June 2010 Clinical Elective   
Department of Gynaecological Oncology, Northwestern Memorial Hospital, 
Northwestern University, Chicago, IL   
  
August 2007 Clinical Elective   
General Surgery Department, Clinical Centre Skopje, Macedonia   
  
July 2006 Clinical Elective   
Pulmonary Diseases/ Clinical Epidemiology, Utrecht Medical Summer School, Holland  
  
LANGUAGE SKILLS   
• Arabic   Fluent, written and spoken   
• English   Fluent, written and spoken   
• French   Conversational    
  
TEACHING   
• Teaching and mentoring of junior colleagues during Obstetrics and 
Gynecology Residency and Clinical Fellowships   
• Presentations at weekly Department rounds in Alexandria University 
and in London Health Sciences Centre.   
• Teaching undergraduate medical students in Alexandria University  
  
PRESENTATIONS   
  
1. Etaby k, Karkour T Road traffic injuries during pregnancy. Safety of different 
imaging modalities. 33rd annual conference [Egypt], June 2015.  
  
2. Etaby k, Elsayed B Ultrasound Guided hysteroscopic resection of submucous 
myoma. 33rd annual conference [Egypt], June 2015.  
  
3. Etaby K, Abdelnabi M Ultrasound in assessment of female infertility. 23rd 
Scientific conference [Egypt]. July 2014  
  
  
PUBLICATIONS / RESEARCH  
  
Primary Interest: My urogynecology Fellowship has built my knowledge to utilize 
noninvasive management to improve general quality of health. My long-term research interest 
is to explore non mesh treatment in female patient presenting with stress urinary incontinence 
Current:    
48 
 
Safety and clinical efficacy of retropubic tension-free vaginal tape 
versus anti-incontinence pessary for treating women with stress 
urinary incontinence: a randomized clinical trial.  
   
       
    Additional research: Current:   
Is there an increased risk of delirium among patients with overactive 
bladder treated with newer anticholinergic medication compared to a 
beta-3 agonist?  
  
Ultrasound-Guided Hysteroscopic resection of submucous myoma: Thesis 
submitted as a partial fulfilment of Master Degree, Alexandria University, 
Faculty of Medicine, May 2015  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
